Amarin Corp Plc (AMRN)

[Tatsumaki]

Cost and side effects will not stop GLP-1 drugs from absolutely destroying V sales in the AD space if both have similar benefit. It'll be the go to drug. Patients will fight for coverage themselves. That doesn't happen with V outside of this board.

Ozempic alone is projected to have annual sales of $100B in 5 years. You know how many insurance company executives you can buy off with that kind of money to ensure your products get preferential coverage for any new indication? Pretty much all of them.